Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Israel warns it can ‘no longer accept’ Hizbollah on its border
    • Millions drop out of China’s state health insurance system
    • Elizabeth Magill resigns as Penn president after antisemitism backlash
    • Jay Powell under pressure to set out plan for US interest rate cuts
    • The west’s Russia oil ban, one year on
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Inside the battle to decarbonise the world’s dirtiest refinery
      • PwC UK imposes restrictions on business-class travel
      • China uranium grab poses threat to western energy supply, warns Yellow Cake
      • Hitachi UK rail plant suffers multimillion-pound writedown
      • Cigna pulls out of blockbuster deal to create insurance giant with Humana
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Wealth Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • India’s NSE set to take Hong Kong’s spot among world’s largest markets
      • The west’s Russia oil ban, one year on
      • China uranium grab poses threat to western energy supply, warns Yellow Cake
      • COP28 fossil fuel pledges will not limit global warming to 1.5C, says IEA
      • ‘Number go up’: bitcoin’s startling surge is inexplicable as ever
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Britain won’t rejoin the EU for decades — if ever
      • Are we all narcissists now?
      • Venezuela’s threat to annex part of Guyana
      • Central banks and the return of the unreliable boyfriend
      • The flawed carbon credit trade needs fixing
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      • Working It
      Most Read
      • Do me a favour: if you help someone at work, don’t expect payback
      • Tom Kerridge: The magic of restaurants requires ‘very hard work’
      • Hospitality bosses share tips for navigating industry challenges
      • FT book award winner Amy Edmondson: Fail fast, fail often-mantras are ‘sloppy’
      • Workers and bosses opt for Christmas payments over parties
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • He blew the whistle on Amazon. He’s still paying the price
      • Jancis Robinson picks the best red wines for Christmas
      • There’s no satisfaction to be found at the internet’s vinyl frontier
      • When I grow up I want to be president
      • The queens of NYC philanthropy
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Eli Lilly & Co

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Thursday, 9 November, 2023
      Pharmaceuticals sector
      Approval for Eli Lilly obesity drug sets up rival to Wegovy

      US and UK regulators say diabetes medication showed ‘significant’ weight loss benefits

      Eli Lilly headquarters in Indianapolis, Indiana,
    • Wednesday, 25 October, 2023
      Drugs research
      New studies find benefits in very early drug treatment of Alzheimer’s

      Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier

      Screen showing brain patterns of an Alzheimer’s patient
    • Tuesday, 24 October, 2023
      Pharmaceuticals sector
      Novo Nordisk and Eli Lilly hoover up smaller obesity drug groups

      Biotech acquisitions this year intended to cement position as market leaders in weight-loss field

      A Wegovy weight-loss drug injection pen
    • Tuesday, 3 October, 2023
      LexMergers & Acquisitions
      Eli Lilly: Point acquisition gives battered biotech sector a boost Premium content

      Cheaper valuations have finally drawn back cash-rich pharmaceutical makers

      Eli Lilly headquarters in Indianapolis
    • Tuesday, 3 October, 2023
      Eli Lilly to buy cancer specialist Point for $1.4bn

      Point is developing radioligand molecules that can deliver targeted radiation to tumour cells

      The Ely Lilly logo on one of the companies’ buildings in San Diego
    • Tuesday, 22 August, 2023
      Pharmaceuticals sector
      Use of horseshoe crabs’ blue blood puts pharma groups under scrutiny

      BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances

      Person holds a horseshoe crab
    • Wednesday, 16 August, 2023
      Pharmaceuticals sector
      Chinese drugmakers develop copycat versions of ‘miracle’ weight-loss drug

      Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication

      A Novo Nordisk factory in Tianjin, China
    • Sunday, 13 August, 2023
      Drugs research
      Eli Lilly achieves hard-won success with Alzheimer’s and obesity drugs

      US pharmaceutical group says it wants to become the first trillion dollar healthcare company

      A pharmacist displays a box of Eli Lilly’s Mounjaro diabetes and weight loss treatment
    • Tuesday, 8 August, 2023
      Lex
      Eli Lilly/Novo: come for the weight loss, stay for other health benefits Premium content

      Drugs that tackle obesity, diabetes and heart disease are good for profits and the public

      A pharmacist holds a box of Mounjaro
    • Tuesday, 8 August, 2023
      Novo Nordisk AS
      Novo Nordisk’s obesity drug cuts risk of strokes and heart attacks

      Shares in Danish drugmaker and US rival Eli Lilly surge to record highs after positive trial of weight-loss drug

      Injector pens for the Wegovy weight loss drug in a box
    • Wednesday, 2 August, 2023
      Pharmaceuticals sector
      Lawsuit alleges blockbuster weight-loss drugs cause ‘stomach paralysis’

      Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk

      Person holding boxes of Ozempic
    • Tuesday, 18 July, 2023
      LexDrugs research
      Alzheimer’s drugs: new medicines bring new hope to dementia battle Premium content

      Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research

      Brain scan from a patient suffering from Alzheimer’s disease
    • Monday, 17 July, 2023
      Dementia
      Eli Lilly drug shown to slow Alzheimer’s progression

      Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment

      Alzheimer’s patient brain scans, provided by Eli Lilly
    • Friday, 23 June, 2023
      Boehringer Ingelheim
      Boehringer Ingelheim enters obesity drug race

      German group aims to join companies whose fortunes have been transformed by weight loss treatments

      An overweight pedestrian
    • Thursday, 18 May, 2023
      LexDrugs research
      Weight-loss drugs: long-term risks could blunt investors’ appetite for remedies Premium content

      Manufacturers racing to build what could be one of industry’s biggest markets must tread with care

      Injection pens of Wegovy, Novo Nordisk’s brand name for semaglutide, a weight-loss medication
    • Monday, 8 May, 2023
      Dementia
      Two Alzheimer’s drugs offer hope to patients after decades of waiting

      In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

      Computer scan of a brain
    • Wednesday, 3 May, 2023
      Eli Lilly to seek US approval after Alzheimer’s drug trial success

      Clinical study results could boost patient access to new class of treatment

      Eli Lilly logo is shown on one of the company’s offices
    • Thursday, 27 April, 2023
      Eli Lilly to seek approval of obesity drug that could disrupt weight loss market

      US pharma group’s late-stage study has shown treatment can slash body weight by nearly a sixth

      An Eli Lilly plant in New Jersey, US
    • Tuesday, 11 April, 2023
      FT News Briefing podcast10 min listen
      Rise of the Russian informer

      Corporate America faces its sharpest drop in profits since the beginning of the Covid pandemic

    • Monday, 10 April, 2023
      Eli Lilly warns EU will miss out on key drugs under planned change to patent rules

      Chief executive says draft plan to cut market exclusivity protection could make pursuing some treatments unviable

      Eli Lilly headquarters
    • Wednesday, 1 March, 2023
      Drug prices
      Eli Lilly to cut price of insulin drugs by 70%

      Pharma group’s decision comes in response to US political pressure over high cost of diabetes medication

      Eli Lilly signage
    • Monday, 16 January, 2023
      Drug prices
      US drugmakers withdraw from NHS pricing agreement as costs soar

      AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales

      AbbVie’s offices in Illinois, US
    • Wednesday, 28 December, 2022
      News in-depthDrugs research
      Race is on to develop new generation of weight-loss drugs

      Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions

    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

      Merck’s Keytruda medication
    • Sunday, 6 November, 2022
      Eli Lilly says some staff want to leave Indiana because of abortion ban

      Chief executive claims Republican state government ‘rushed’ process when passing sweeping restrictions

      Pro-choice demonstrators gather at Indiana University in Bloomington to rally in support of women’s reproductive rights
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Israel-Hamas war
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
      • Artificial intelligence
      • Semiconductors
      • Cyber Security
      • Social Media
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Wealth Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      • Working It
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In